The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the company
Post-acquisition of the balance 25% outstanding shares will result into Sun Pharma de México, S.A. de C.V. becoming a wholly-owned subsidiary of the company.
The delegation's visit covered a wide range of topics
Capital raise to accelerate product and technology development and support expansion efforts to reshape communications to HCPs across the globe
The investment will help the company meet soaring demand for user-friendly oral dosage form development and manufacturing
The AGE1.CR.pIX cell line's versatility allows it to support a wide range of viruses and vaccine types
‘Sanjeevani’ aims to raise awareness and encourage conversations around the silent cancer epidemic
Kivo’s expanded platform brings compliant collaboration and intelligent process automation to emerging Regulatory, Clinical and Quality teams
Commenced operations in flood-affected Himachal Pradesh
Subscribe To Our Newsletter & Stay Updated
